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Abstract
Background: A wealth of information on the functional roles 
of docosahexaenoic acid (DHA) and arachidonic acid (ARA) 
from cellular, animal, and human studies is available. Yet, 
there remains a lack of cohesion in policymaking for recom-
mended dietary intakes of DHA and ARA in early life. This is 
predominantly driven by inconsistent findings from a rela-
tively small number of randomised clinical trials (RCTs), 
which vary in design, methodology, and outcome measures, 
all of which were conducted in high-income countries. It is 
proposed that this selective evidence base may not fully rep-
resent the biological importance of DHA and ARA during 
early and later life and the aim of this paper is to consider a 
more inclusive and pragmatic approach to evidence assess-
ment of DHA and ARA requirements in infants and young 
children, which will allow policymaking to reflect the marked 
diversity of need worldwide. Summary: Data from clinical 
RCTs is considered in the context of the extensive evidence 
from experimental, animal and human observational stud-
ies. Although the RCT data shows evidence of beneficial ef-
fects on visual function and in specific cognitive domains, 
early methodological approaches do not reflect current 
thinking and this undermines the strength of evidence. An 
outline of a framework for an inclusive and pragmatic ap-
proach to policy development on dietary DHA and ARA in 
early life is described. Conclusion: High-quality RCTs that will 
determine long-term health outcomes in appropriate real-
world settings need to be undertaken. In the meantime, a 
collective pragmatic approach to evidence assessment, may 
allow public health policymakers to make comprehensive 
reasoned judgements on the merits, costs, and expediency 
of dietary DHA and ARA interventions.
© 2018 The Author(s) 
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Introduction
Although the importance of fatty acids for human 
health and well-being was initially recognised almost 90 
years ago [1, 2], it is during the last 3 decades that there 
has been considerable interest to understand the roles of 
long chain polyunsaturated fatty acids (LCPUFAs) in in-
fant growth and development [3–7]. The seminal work of 
Manuela Martinez showing the rapid accretion of doco-
sahexaenoic acid (DHA) and arachidonic acid (ARA) by 
the infant brain during the first 1,000 days of life [8], was 
the driver for many scientists, clinical researchers, nutri-
tionists, developmental psychologists and epidemiolo-
gists to contribute to this important research domain. 
Although there is now a wealth of information on the 
functional roles of DHA and ARA from cellular, animal 
and human studies, there remains a lack of cohesion in 
policymaking on dietary intakes of DHA and ARA in 
early life [9–11]. This predominantly relates to inconsis-
tent findings from a small number of randomised clini-
cal trials (RCTs). RCTs in infants born at term have been 
the subject of 4 Cochrane systematic reviews [12–15]. 
These have each concluded that routine supplementa-
tion of full-term infant formula with LCPUFAs cannot 
be recommended at this time [12–15]. Although the in-
cluded RCTs have been rigorously reviewed, they vary 
considerably in design, methodology and outcome mea-
sures, and were all conducted in high-income countries. 
This selective evidence base may not fully represent the 
biological importance of DHA and ARA during early 
and later life, and consequently, current national and in-
ternational policies may not adequately serve the needs 
of all infants and children at a time of rapid growth and 
development.  
The aim of this paper is to examine the need for a more 
inclusive and pragmatic approach to evidence assess-
ment and policymaking, which will be more sensitive to 
the DHA and ARA requirements of all children world-
wide. 
Grading the Strength of Evidence when Assessing 
Health Care Interventions
Cochrane reviews are undertaken using the Grading of 
Recommendations Assessment, Development, and Eval-
uation (GRADE) system for rating quality of evidence 
and grading strength of recommendations in systematic 
reviews [16]. The GRADE approach results in an assess-
ment of the quality of a body of evidence according to one 
of four grades – High: confident that the true effect lies 
close to the estimate of effect; Moderate: The true effect is 
likely to be close to the estimate of effect but may be sub-
stantially different; Low: The true effect may be substan-
tially different from the estimate of effect; and Very low: 
The true effect is likely to be substantially different from 
the estimated effect. Key elements of studies that may in-
fluence the strength of evidence include design and meth-
ods, dose-response associations, magnitude of effect, at-
trition rates and risk of bias that may decrease or increase 
the observed effect and the estimated overall health gain 
within the target population. 
RCTs are generally viewed as high-grade evidence. 
However, this can be altered if assessment demonstrates 
that there are study limitations based on how the RCTs 
were conducted and whether there are weaknesses in key 
domains, for example, sample size and attrition [17–19]. 
In contrast, observational studies are generally assumed 
to provide evidence of lower grade because of the higher 
risk of bias attributable to lack of randomization and in-
ability of investigators to control for known or unknown 
confounding factors. However, the strength of the evi-
dence base for observational studies may be raised by 
methodological qualities such as large sample size and ro-
bust long-term data [17–19]. With these potential chang-
es in strength of evidence, it is important that evidence 
from all research sources is included in the assessment 
process, and this is particularly relevant in public health 
interventions. 
Early Dietary Intake of DHA and ARA – What Is the 
Evidence of Health Benefit from RCTs?
The objective of the Cochrane reviews was to assess 
whether supplementation of formula milk with  LCPUFAs 
is both safe and beneficial for full-term infants, while fo-
cusing on effects on visual function, neurodevelopment 
and physical growth [12–15].
In each of the reviews, only randomised and quasi-
RCTs were eligible for inclusion, and the studies selected 
for review compared infant formula enriched with DHA 
plus ARA or DHA alone, with infant formula that was 
devoid of these fatty acids. The LCPUFA supplements 
could be from any source including fish oil, egg triglyc-
erides or algal oils. Eligibility for inclusion required the 
following criteria – infants were ≥37 weeks of gestation 
at birth; study formula was commenced within 2 weeks 
after birth; study formula was the only source of milk 
from the time of randomisation until at least 8 weeks of 
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age; and a minimum of 3 months follow-up data on clin-
ical outcomes of interest were available for analysis. 
Types of outcome measures included visual acuity (mea-
sured using either Tellers cards or visual evoked poten-
tials), neurodevelopmental outcomes (General Quotient, 
Intelligent Quotient and other measures of cognitive 
functions), and physical growth (weight, length and head 
circumference). 
The initial review in 2001 [12], included a final selec-
tion of 9 studies and in the most recent review [15], 31 
studies were identified as potentially eligible, but follow-
ing evaluation, only 15 were included. The final selection 
of studies emerged from the GRADE system of rating 
quality of evidence and grading strength of recommenda-
tions in systematic reviews [16]. The reasons for exclu-
sion of 16 studies from the final analysis were – infants 
also received breast milk, late introduction of interven-
tion formula or the formula contained other nutrients of 
interest, only laboratory outcomes were measured, study 
was not blind or methods were not clear. 
In the most recent review [15], it was noted that there 
were no new cohorts since 2011, although there had been 
further follow-up of the previous cohorts. Therefore, with 
almost all the studies having been included in the previ-
ous reviews, it is not surprising that the conclusions in the 
2017 review were in keeping with those of previous re-
views. It was concluded that the majority of the RCTs did 
not show beneficial effects of LCPUFA supplementation 
on the neurodevelopmental outcomes of term infants, 
that the beneficial effects on visual acuity had not been 
consistently demonstrated, and finally, that routine sup-
plementation of term infant milk formula with LCPUFA 
cannot be recommended [15]. The reviewers did not ex-
press any concern regarding the safety of supplementa-
tion of infant formulas with DHA and ARA. However, 
data on high-dose intervention is limited and Colombo 
and colleagues have indicated that sustained attention 
may be attenuated with DHA concentrations that are 3 
times that of breast milk [20]. 
Although the studies had been rigorously assessed 
from a design and methodology perspective, they are a 
small disparate group of studies, demonstrating marked 
variation in intervention source of fatty acids (egg phos-
pholipid, algae, and fish oil), dose and duration of inter-
vention, unknown levels of DHA and ARA intake from 
complementary foods, differences in age at assessment, 
and a diverse range of assessments (Table 1). With this 
level of heterogeneity, it is difficult to draw an overriding 
view on the health benefits of LCPUFAs in early life. 
However, several studies did show evidence of beneficial 
effects on visual function, especially where there was a 
combination of high dose and longer intervention dura-
tion, and in specific cognitive domains including prob-
lem solving and attention control (Table 1). 
The heterogeneity in the design and methodology 
used in the RCTs can be partly explained by the fact that 
the studies were undertaken over a period lasting 2 de-
cades and included the first RCTs of LCPUFAs under-
taken in newborn infants. Understandably, the initial 
designs and methods reflect a high level of caution and 
are not representative of current thinking on dose and 
duration of the intervention, and choice of assessments 
[17]. None of the studies allowed for the effects of fatty 
acid desaturase genotype on fatty acid status, and al-
though current evidence indicates that the impact on 
ARA levels, and to a lesser extent DHA, is limited com-
pared to dietary intake, this variable should be consid-
ered in future studies [21]. It is also surprising that DHA 
and ARA status of the participants was not routinely 
measured in several of the included studies at the time 
of recruitment and assessment to confirm differences in 
status between intervention and control groups. More-
over, all the studies included in the review were under-
taken in high-income countries, and on reflection it is 
very likely that many of the participants were not DHA 
or ARA deficient [18]. This would clearly attenuate the 
effects of the intervention and importantly, would con-
ceal potential beneficial effects in infants with low LCP-
UFA status. 
It is important that researchers and policymakers dis-
tinguish between the appraisal of evidence and the pro-
cess of making policy [19]. The comment by the Cochrane 
reviewers that supplementation cannot be recommended 
based on this RCT data is an appraisal of the evidence 
based on their systematic review. However, public health 
interventions are intended to promote or protect health 
in communities or populations, and therefore policymak-
ing has a broader perspective, which includes reducing 
inequality and protecting the most vulnerable [19]. The 
deficiencies in the reviewed RCTs that have been report-
ed [17] should not only provide learning for researchers 
and future RCTs but also provide a marker for policy-
makers as they determine which evidence will provide the 
best policy on dietary LCPUFAs for vulnerable infants 
and young children worldwide. 
If new RCTs, which will address past methodological 
issues and are conducted in appropriate real-world set-
tings, are now commenced, definitive long-term data on 
health outcomes will not be available for several years. 
This presents a dilemma for public health policymakers – 
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do they simply wait for RCT data to become available, or 
do they endeavour to protect the interests of infants and 
young children, especially those living in medium- and 
low-income countries, by assessing the broader evidence 
base and develop policies that are based on broad rea-
soned judgement? 
What Do Experimental and Animal Studies Tell Us 
about DHA and ARA in Early Life?
The n-3 LCPUFAs influence cellular membrane struc-
ture and function [3–7], and DHA is especially important 
in the brain and retina, where it rapidly accumulates dur-
ing the early years of life [8]. DHA is also the precursor of 
potent lipid mediators called resolvins and protectins, 
which play crucial roles in the prevention or treatment of 
common chronic diseases that may lead to significant 
morbidity and mortality. The n-6 LCPUFAs, particularly 
ARA, are widely distributed throughout human cells and 
tissues [6]. In addition to the central nervous system 
where ARA plays an essential structural and functional 
role, ARA is also a metabolic requirement for all cells as 
a precursor for eicosanoids that modulate a variety of bi-
ological processes, particularly those relating to cerebral, 
cardiovascular and immune function [6].
To assess the level of interest in experimental and ani-
mal research relating to DHA, an audit of all papers pub-
lished on Medline over a 12-month period (January 1, 
2016 to December 31, 2016) was undertaken [22]. The 
search terms included (“docosahexaenoic acids” [MeSH 
Terms] OR (“docosahexaenoic” [All Fields] AND “acids” 
[All Fields]) OR “docosahexaenoic acids” [All Fields] OR 
(“docosahexaenoic” [All Fields] AND “acid” [All Fields]) 
OR “docosahexaenoic acid” [All Fields]) AND (“animals” 
[MeSH Terms:noexp] OR animal [All Fields]) AND 2016 
[Date – Publication]. This search of a single research da-
tabase identified 95 publications during the 12-month 
search period, with 45 classified as primary scientific re-
search, 20 human studies, observational and RCT studies, 
27 reviews, and 3 studies that were considered not rele-
vant. 
During the 12-month period, there were 45 publica-
tions providing original scientific research on the role and 
function of DHA with a focus on cellular metabolism or 
effects on specific organ tissue, with studies relating to 
brain and immune function being most prevalent. The re-
search findings confirmed that DHA is metabolically rel-
evant at all stages of the human life course, and that DHA 
and its derivatives interact at multiple levels, including cell Re
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membrane composition, metabolism, signal transduction 
and amplification and gene expression. The relationship 
of DHA to different biological systems throughout the hu-
man life course, underlines the importance of taking a 
whole life perspective when considering the dietary needs 
for DHA and other LCPUFAs in early life.
The number of papers relating LCPUFAs to immune 
function reflects the increasing evidence that a chronic 
low-grade inflammatory state is a pathological feature of 
a wide range of chronic conditions, including the meta-
bolic syndrome, nonalcoholic fatty liver disease, type 2 
diabetes mellitus, and cardiovascular disease. There is 
emerging information on novel mechanisms of action by 
dietary fatty acids of different classes influencing inflam-
matory processes, some acting through proinflammatory 
and others through anti-inflammatory or inflammation-
resolving mechanisms [23, 24]. Moreover, the balance be-
tween DHA and ARA is considered to have important 
immunomodulatory roles during the postnatal period 
when the immune system is rapidly developing; interven-
tion studies have demonstrated improvement in many 
markers of immune function in infants fed formula sup-
plemented with ARA and DHA compared with unsup-
plemented formula, and this is associated with beneficial 
health outcomes including reduction in the risk of devel-
oping allergic and atopic disease early in life [25].
The MEDLINE search identified 27 review articles, 18 
referring to animal and human studies and 9 were exclu-
sively related to human studies. A common theme was 
that outcome measures were more consistent in animal 
intervention studies, and translating this evidence to 
health outcomes in humans has been challenging. This 
discrepancy between animal and human data may par-
tially relate to variance in methodology. In animal stud-
ies, the duration of dietary intervention is significantly 
longer than in human intervention studies, when adjust-
ed for the respective life expectances. The average age at 
which mice attain puberty is 42 days, which is frequently 
the duration of nutritional interventions in mice, includ-
ing recent DHA studies [26]. There are no known human 
RCTs where the dietary intervention was initiated at birth 
and continued until puberty. The original rat studies by 
George and Mildred Burr showed that it was several 
months of total exclusion of fatty acids before the rats 
showed obvious clinical signs of essential fatty acid defi-
ciency [2]. It may be that longer duration of intervention 
in humans will demonstrate later programming effects. 
Data from the Cochrane review shows that in the major-
ity of the RCTs involving DHA and ARA supplementa-
tion, the duration of supplementation was 4 months, 
which is approximately 2–3 days in the life of a mouse 
[27]. There are specific domains that may be sufficiently 
sensitive to DHA and ARA and produce effects within a 
relatively short period of intervention, but an expectation 
that global neurodevelopment will be influenced by 
4 months of supplementation is probably unrealistic. 
What Do Observational Studies Tell Us About DHA 
and ARA in Early Life?
The MEDLINE search also identified 20 observation-
al studies. Observational studies may represent a more 
feasible study design for evaluating public health inter-
ventions than RCTs [19]. While RCTs (notably cluster 
RCTs) can be designed to evaluate even complex public 
health programs, often they are not feasible because of 
logistic or resource constraints. Even a carefully planned 
study such as the Promotion of Breastfeeding Interven-
tion Trial, which was described as the largest RCT of hu-
man lactation, and was led by 2 international research 
teams from Canada and England, and conducted in a 
country that is structured and organised, the cluster ran-
domisation model was undermined by the unexpected 
withdrawal of 3 clusters. This led to an imbalance in the 
randomisation model and the analysis needed to include 
adjustments for potential confounding variables, as is 
done in observational studies [28]. With the scientific, 
logistic, and financial pressures in conducting long-term 
RCTs, it may be constructive to pragmatically balance 
the need for a robust study design with the need for evi-
dence that is inclusive and relevant to the needs of the 
target population. Under these circumstances, an obser-
vational study may not only be informative but also per-
ceived as being low risk, cost effective and scientifically 
appropriate. 
There have been several interesting observational 
studies that investigated the relationships between di-
etary or circulating n-3 LCPUFAs and all-cause mortal-
ity, and these have recently been assessed by a system-
atic review and meta-analysis that included 11 prospec-
tive observational studies [29]. The studies included 
371,965 participants from general populations and con-
sidered 31,185 death events. From this analysis, the 
dose-response indicated that for each 0.3 g/day incre-
ment in n-3 LCPUFA intake, there was an associated 
6% lower risk of all-cause mortality and for each 1% 
increment in the proportions of circulating DHA and 
EPA in total fatty acids in blood there was an associated 
21 and 20% decreased risk of all-cause mortality respec-
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tively. Moderate to high heterogeneity was observed 
across the analysis, but the authors concluded that the 
findings suggest that both dietary and circulating 
 LCPUFA are inversely associated with all-cause 
 mortality [29].  
Hibbeln et al. [30] utilized data from the Food and 
Agriculture Organisation (FAOSTAT) [35] to measure 
n-3 LCPUFA dietary intake in 38 predominantly devel-
oped countries and related that data to age-adjusted 
mortality due to cardiovascular disease, coronary heart 
disease, and stroke. They determined that the greatest 
protection was provided by a total n-3 LCPUFA dietary 
intake of 750 mg/day, which most closely correlated with 
the dietary intake of the Japanese population. They com-
mented that Japan is a modern industrialized society 
with a large population and well-documented rates of ill-
nesses and nutrient intakes. Low rates of cardiovascular 
disease have been consistently reported in Japan, despite 
high rates of smoking and hypertension [34]. Moreover, 
when the Japanese move to the United States and con-
sume a diet low in n-3 LCPUFAs, the risk of cardiovas-
cular disease increases, suggesting that the protective ef-
fect is not genetic [31].
In a multinational study, published mathematics test 
scores from the Program for International Student As-
sessment of the Organization for Economic Coopera-
tion and Development, which is a single test that is ad-
ministered in a consistent way to 15-year-old students 
in 59 countries, were related to national data on mater-
nal milk DHA levels in 28 high- and medium-income 
countries from both the Northern and Southern Hemi-
spheres [32]. The findings showed a strong correlation 
between breast milk DHA levels and cognitive perfor-
mance in the mathematics test with the observed asso-
ciation remaining highly significant after controlling for 
national wealth, investment in education and macronu-
trient intake.
Although observational studies tend to raise further 
research questions, multinational observation studies 
that, for example, relate early life dietary intake of DHA 
(and other LCPUFAs) to later life health outcomes, mer-
it consideration by public health policymakers. 
What Is the Best Evidence for Public Health 
Policymakers?
To increase the value of health care services, many 
countries have established programs or independent 
agencies that inform health care decision-making 
through systematic reviews of healthcare interventions, 
for example, the National Institute for Health and Clin-
ical Excellence in the United Kingdom [33] and in the 
United States, the Agency for Healthcare Research and 
Quality created the Effective Health Care (EHC) Pro-
gram in 2005 [34]. A key element of the EHC program, 
is the Comparative Effectiveness Review, the aim of 
which is to determine how the relative benefits and 
harms of a range of options compare, rather than to an-
swer a narrow question on whether a single therapy is 
safe and effective [35–38]. As noted in the Cochrane 
reviews of LCPUFAs, it is not unusual for the number 
of RCTs that are available to provide direct comparisons 
to be relatively small, and there is then a risk that the 
body of evidence is insufficient to draw robust conclu-
sions about comparative benefits and harms. It is also 
noted that in the 2017 review [15], there were no new 
cohorts since 2011. Under these circumstances, there is 
a need to seek a more wide-ranging opinion from the 
research literature, including evidence from experimen-
tal studies, placebo-controlled trials, and observational 
studies. 
In the consideration of observational studies by Com-
parative Effectiveness Reviews, it is emphasised that sys-
tematic reviewers should answer 2 specific questions – 
first, are there gaps in the RCT evidence to satisfactorily 
address the review questions that are under consider-
ation? And second, will observational studies provide val-
id and useful information to address these key questions? 
[35, 38]. It is clearly stated that there is no a priori reason 
to exclude observational studies from research questions 
on health benefit, but they should be evaluated on the 
same criteria used to evaluate the inclusion of RCT data, 
namely, whether the observational study results address 
the key question and whether the observational data are 
likely to be valid.
It is also noted that in relation to applicability of ev-
idence, and the relevance to the target population and 
setting, observational studies may be particularly in-
sightful [35–38], and therefore, they may be particu-
larly relevant in public health interventions that focus 
on promoting or protecting health at community and 
national levels. The public health considerations of a 
specific health issue within a population will generally 
include – the perceived magnitude and importance of 
the problem, the potential effectiveness and harms of an 
intervention, the feasibility of its implementation, and 
its political and public acceptability [19]. Decision-
making around dietary LCPUFAs in early life is an im-
portant public health issue, and for informed policy de-
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cision-making, a broader examination of the 
 literature may allow the process to progress from re-
search  evidence to policy implementation in a timelier 
manner. 
Is There Evidence of Inadequate Dietary Intakes of 
DHA and ARA in Early Life?
The World Health Organisation (WHO) recommends 
that mothers worldwide exclusively breastfeed infants for 
the child’s first 6 months to achieve optimal growth, de-
velopment and health. Thereafter, they should be given 
nutritious complementary foods and continue breast-
feeding up to the age of 2 years or beyond [39]. It is rec-
ognised that additional nutrient dense complementary 
foods (liquid and solid) are required following the exclu-
sive breastfeeding period to prevent under-nutrition and 
stunting in the childhood population [40]. 
Human milk is a complex dynamic bioactive fluid 
which, in addition to containing essential nutrients for 
normal growth and development, has several composi-
tional components that make it unique. Unlike infant for-
mula, which is standardised within a very narrow range 
of composition, human milk composition is dynamic, 
and varies during a feeding, diurnally, during the period 
of lactation, and between mothers and populations [41]. 
A potent example of human milk uniqueness is the con-
sistent presence of significant quantities of DHA and 
ARA [42, 43] and this contrasts with the trace amounts 
that may be found in cow’s milk, goat milk, soya milk and 
rice milk [44]. The level of availability of DHA and ARA 
in human milk, as opposed to that in other animal and 
plant milks, is highly indicative of their essentiality for 
human infants. Moreover, there are documented mecha-
nisms that actively transport DHA and ARA through the 
placenta from the mother to the fetus during pregnancy 
[45] and for DHA and ARA to be released from maternal 
lipid stores and transported to the breast during lactation 
[46]. These evolutionary mechanisms enhance the deliv-
ery of DHA and ARA to the fetus during the prenatal pe-
riod and to the infant post birth. Endogenous synthesis of 
DHA and ARA is limited in infants [47] and therefore the 
infant is dependent upon dietary sources of both DHA 
and ARA. 
Amounts of DHA and ARA in human milk tend to 
vary by maternal diet and nutritional status [42, 43]. 
Based on data from 65 studies of milk from 2,474 wom-
en, the mean concentration of ARA (% fatty acids by 
weight) was 0.47% (range 0.24–1.0%) and the mean con-
centration of DHA was 0.32% (range 0.06–1.4%). The 
levels of DHA were particularly low in populations with 
the greatest poverty – 0.06% DHA in Pakistan, Northern 
Sudan, and 0.10% DHA in Southern Sudan [42]. Apply-
ing the WHO recommendation on exclusive breast feed-
ing for 6 months, it is estimated that at 6 months, infants 
will be receiving approximately 171 mg/day of ARA and 
111 mg/day of DHA, based on a breast milk intake of 854 
mL/day [48] and the reported mean concentrations of 
DHA and ARA in human milk [42]. An infant receiving 
a formula without supplemented DHA and ARA will 
clearly have zero consumption from milk feeds during 
this time and it has been shown that these infants not 
only have lower blood levels of DHA [49], but the accre-
tion of both DHA and ARA in the brain is significantly 
lower in infants fed a formula that is devoid of these fat-
ty acids [49, 50]. 
Complementary foods tend to have low concentra-
tions of DHA and ARA and this is evident in both high- 
and low-income countries [51–54]. In low-income 
countries, it is common practice for weaning infants to 
receive the food from the family bowl, which is most 
commonly of plant origin and will have low ARA and 
DHA content. In a recent publication, the dietary intake 
of ARA and DHA at the population level was strongly 
related to the economic status of the country [55]. The 
analysis was based on food consumption data originally 
collected by the Food and Agriculture Organisation 
(FAO) [56] and by applying food composition tables, 
the per capita dietary intakes of DHA and ARA were 
estimated for 175 countries worldwide, with 47 classi-
fied as developed and 128 as developing. This analysis 
demonstrated that per capita intakes of both fatty acids 
varied significantly in relation to the gross national in-
come of the country, with low-income countries having 
intakes of DHA and ARA, which were only 20–25% of 
that of high income countries. The 28 countries in the 
lowest income category had per capita median DHA 
and ARA intakes of 47 and 43 mg/day, respectively, and 
this group represents a total population of nearly 740 
million people. There was considerable regional varia-
tion with lowest intakes for both ARA and DHA being 
in Sub-Saharan Africa and Southern, Western and Cen-
tral Asia [55].
Estimates were also made of DHA and ARA intakes 
during the age period of 6–36 months [57]. This analysis 
estimated intakes of DHA and ARA from breast milk and 
complementary foods using published data on median 
duration of breast feeding, mean concentration of DHA 
and ARA in breast milk, and mean intakes of breast milk. 
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The dietary intakes of DHA and ARA in infants and 
young children aged 6–36 months from 76 developing 
countries (17 upper middle income, 34 lower middle in-
come, and 25 low income) were 48.8 and 63.7 mg/day 
respectively. The contribution of DHA and ARA intake 
from complementary foods was directly related to the 
gross national income of the country and the intakes of 
DHA and ARA from complementary foods following the 
discontinuation of breast feeding for the 76 countries 
were 14.6 and 17.9 mg/day, respectively, and in the low-
est income countries, intakes fell to 9.6 and 8.9 mg/day 
respectively. The DHA and ARA intake from comple-
mentary foods was exceptionally low in the poorest re-
source countries, especially Nepal (DHA 0.7 mg/day; 
ARA 1.1 mg/day), Ethiopia (DHA 1.1 mg/day; ARA 3.8 
mg/day), and Rwanda DHA 1.8 mg/day; ARA 1.7 mg/
day) [57, 58].
This evidence, which was based on data originally 
collected by the FAO, shows that many millions of in-
fants and young children, especially the most vulnerable 
living in low-income countries have a dietary intake of 
DHA and ARA, which is significantly low compared to 
current international recommendations. The FAO has 
provided specific recommendations on dietary intakes 
of DHA in infants and young children stating that from 
0–6 months the daily requirement is 0.1–0.18%E of 
DHA (equivalent to a mean of 102 mg/day); for 6–24 
months, DHA requirement is 10–12 mg/kg bodyweight 
(equivalent to 70–120 mg/day); for 2–4 years, DHA and 
EPA 100–150 mg/day, with DHA and EPA increasing to 
200–250 mg/day at age 6–10 years [10]. In 2013, the 
 European Food Safety Authority recommended an ad-
equate intake of 100 mg/day DHA for older infants 
(>6 months of age) and young children below the age of 
24 months [59] and in 2014, European Food Safety Au-
thority determined adequate nutrient intakes of LCPU-
FA from birth to the age of 24 months as 100 mg DHA/
day [9]. There are few explicit dietary recommendations 
for ARA. However, an expert advisory group recom-
mended that during the first months of life, infants 
should receive 140 mg ARA/day [60]. A study in Bel-
gium noted that in children 2.5–3 years of age, the DHA 
intake was 45 mg/day and for ARA 17 mg/day, indicat-
ing that intake in this high-income country, was signifi-
cantly below recommended levels [61]. Codex Alimen-
tarius has identified DHA as an optional ingredient for 
infant formulas and stated that if DHA is added to infant 
formula, a guidance upper level should be 0.5% fatty ac-
ids, the ARA content should reach at least the same con-
centration as DHA; and the content of eicosapentaenoic 
acid that can occur in sources of LCPUFA, should not 
exceed the content of DHA. National authorities may 
deviate from the above conditions, as appropriate for the 
nutritional needs [62]
The consequences of an inadequate intake of DHA 
and ARA, and other key nutrients, are preventable. Re-
searchers, healthcare workers, policymakers, and other 
key actors need to consider the level of evidence re-
quired and decide what actions are appropriate for this 
strength of evidence. The transferability of the evidence 
into practice requires a weighing of multiple factors 
such as the perceived magnitude and importance of the 
problem, the potential effectiveness and harms of the 
intervention, the feasibility of its implementation, its 
political acceptability and the public demand for action 
[19]. Although different interest groups may advocate 
for competing recommendations based on the same ev-
idence, it is critical that the dietary needs of the most 
vulnerable infants are at the center of the discussion. 
Progress will require a pragmatic approach, which may 
become incremental, as future evidence becomes avail-
able. To reach an agreement on the balance between the 
level of evidence and the measures required to address 
the need, a framework consisting of key questions is pro-
posed (Appendix). 
Conclusions
Relating early life nutritional interventions to later life 
health outcomes is always going to be challenging and all 
research methods will have their limitations. There is a 
real concern that inconsistency in RCTs of LCPUFA sup-
plementation may be misinterpreted as indicating that 
low dietary intake of DHA and ARA will be of no conse-
quence to even the most vulnerable infants. Recent evi-
dence indicates that a high proportion of the global child-
hood population may be at risk of LCPUFA deficiency in 
early life [55, 57, 58].
It is important that the body of research available to pol-
icymakers reflects the socio-economic, cultural, dietetic 
and genetic diversity of the populations being considered, 
and that studies are inclusive and focus on those individu-
als and communities that are at greatest risk. In some set-
tings, observational studies may represent the most feasible 
and appropriate study designs for identifying at-risk popu-
lations and evaluating public health interventions. 
With the first 1,000 days of life being a critical period 
for normal growth and development, a key objective of an 
incremental pragmatic approach to dietary DHA and 
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ARA in early life should be to establish an LCPUFA safe-
ty net for the most vulnerable infants worldwide. This can 
be achieved by ensuring that levels of DHA and ARA in 
infant formulas, follow-on formulas, and complementary 
foods reflect published data on median levels of DHA and 
ARA in breast milk. 
Appendix
An Evaluation Framework for a Pragmatic Approach to Policy 
Issues on Dietary DHA and ARA in Early Life
Why Is a Pragmatic Approach Being Considered?
A key principle of the EHC Program is that the questions that 
are being addressed in reviews must be answered at a time when 
decision makers need the information. The slow and unpredict-
able translation of research into practice has been linked to the as-
sertion that the evidence base should be developed through tradi-
tional explanatory models and efficacy designs rather than be the 
product of more pragmatic methodologies. Pragmatic models 
such as those adopted by the EHC have evolved to identify benefits 
and potential harm and to address practical issues that may pro-
vide momentum to the translation of research evidence to effective 
implementation.
The distinction between the appraisal of research evidence and 
the process of making policy is particularly important when con-
sidering what question(s) needs to be answered. From a research 
perspective, the Cochrane review asked the question – Is DHA and 
ARA supplementation of infant formulas beneficial and safe? A 
public health policy question that views the issue from a popula-
tion perspective could be – Should measures be taken to ensure 
that at-risk infants and young children receive food sources that 
will adequately complement their current low DHA (and ARA) 
intakes? Clearly these questions are not mutually exclusive, if the 
evidence from the first question indicated that there was no evi-
dence of benefit and that the intervention was potentially harmful, 
public health policymakers would reject their policy proposal. 
However, as there is some evidence of benefit, there is no evidence 
of harm, and there is non-RCT evidence indicating that inadequate 
dietary intake of DHA and ARA in early and late life has poten-
tially serious health consequences, the pragmatic public health 
question has merit and justifies consideration. 
What Is the Driver for this Public Health Policy Question?
The main complementary food source for DHA is oily fish and 
for ARA meat, poultry and eggs. Any child who has a diet that is low 
in marine and animal foods will become deficient in these fatty acids. 
Recent published evidence indicates that dietary intakes of DHA and 
ARA in infants and young children aged 6–36 months are signifi-
cantly lower than current recommendations, especially in low in-
come countries [55, 57, 58]. From a policy perspective, the issue 
meets the principal objectives of public health policies which are to 
improve population health, avoid harm and reduce health inequality. 
What Is the Magnitude of the Issue?
The WHO has stated that childhood stunting is one of the most 
significant impediments to human development globally, affecting 
approximately 162 million children under the age of 5 years. It is 
a largely irreversible outcome of inadequate nutrition and repeat-
ed bouts of infection, during the first 1,000 days of a child’s life. 
Inadequate provision of complementary foods, especially animal 
foods, is a key factor in the development of acute malnutrition, 
stunting and mortality. With low intakes of marine and animal 
food, (and therefore low intakes of DHA and ARA), being associ-
ated with stunting, DHA and ARA food sources or supplements 
need to be made available to infants and young children who are 
at greatest risk [55, 57, 58]. If current trends continue, projections 
indicate that 127 million children under the age of 5 years will be 
stunted in 2025 [63]. WHO global recommendations on comple-
mentary feeding encourage consumption of healthy, diversified 
diets, including high-quality, nutrient-rich, animal source food 
during the period 6–23 months [40]. 
What Is the Evidence to Support a Pragmatic Dietary DHA 
and ARA Intervention in Early Life?
There is lack of consistency in the evidence from RCTs and 
this is related to weaknesses in design and methodologies, espe-
cially in early studies. Although there is evidence of benefit in vi-
sion and some specific aspects of cognition, there are learning 
points for new-quality RCTs that need to be conducted in appro-
priate settings. While the outcome of these studies is awaited (and 
this may be in several years), it is important to consider other 
supporting evidence that is emerging from experimental, animal, 
and observational data, including the immunomodulatory roles 
of DHA and ARA in early life, when the immune system is rap-
idly developing. A pragmatic approach that is based on the total-
ity of evidence can begin to constructively address the inadequate 
dietary intake of DHA and ARA in the at-risk infant and child 
population. 
What Is the Intervention, How Will It Be Implemented, and 
How Will Outcomes Be Measured?
The main objective of the intervention will be to increase the 
availability of DHA and ARA food sources and relevant nutri-
tional products for at-risk populations, and this should be part of 
a wider initiative to promote effective coordination and collabora-
tion through integrated, multisectoral action, supported by effec-
tive governance of food systems at all levels, and facilitated by 
high-level political support. Maintaining the momentum of 
growth in agricultural productivity will be crucial in the coming 
decades with a stronger focus on nutrient-dense foods such as 
fruits, vegetables, legumes and animal-source foods. These ac-
tions need to be supported by nutrition, health, and education 
institutions, industry and other professional and voluntary organ-
isations. Food sources for DHA and ARA, and specific nutrition-
al products are currently widely available in high-income popula-
tions and this availability now needs to extend to countries in 
greatest need. Inherent within the pragmatic approach is a flexi-
bility that will allow opportunities for local teams and communi-
ties to have local ownership of the policy and investigation of the 
effects of implementation, and be able to make refinements to the 
process, based on intermittent evaluation and real-time and real-
world data. 
Is This a Cost-Effective Solution?
Malnutrition imposes unacceptably high costs on society in hu-
man and economic terms. Recent research showed that investing 
US$1.2 billion annually in micronutrient supplements, food forti-
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fication and biofortification of staple crops for 5 years would gen-
erate annual benefits of US$15.3 billion, a benefit-to-cost ratio of 
almost 13–1, and this would result in better health, fewer deaths 
and increased future earnings [6]. Child and maternal malnutri-
tion is the largest nutrition health burden in the world.
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